Session translationnelle #1 : Cardiovasculaire

mardi 11 juin 2024
Sessions translationnelles
Sessions translationnelles • S11 • 13h30 > 15h00 • Session translationnelle #1 : Cardiovasculaire • Amphi E Sessions translationnelles
Modérateurs : Perle TOTOSON (Besançon), Zoubir DJERADA (Reims)

Conférence invitée
13h30 Le co-transporteur sodium-glucose2 (SGLT2): une nouvelle cible thérapeutique dans le dysfonctionnement des cellules endothéliales menant aux pathologies cardiovasculaires - Valérie SCHINI-KERTH (Strasbourg)

Communications orales
• 44 • CO-001 - Population pharmacokinetic modeling of apixaban in end-stage kidney disease (ESKD) patients with atrial fibrillation receiving hemodialysis > C. Celine Konecki • 151 • CO-002 - Suicidal behaviour and Elexacaftor/Tezacaftor/Ivacaftor: a case series and disproportionality Analysis Using the WHO Pharmacovigilance Database > J. Justine Perino • 162 • CO-003 - Use of sodium glucose co-transporter 2 inhibitors in hospitalized patients: a cross sectional study using a clinical data warehouse > M. Maxime Demourgues • 188 • CO-004 - The Flavonoid Resokaempferol Improves Insulin Secretion from Healthy and Dysfunctional Pancreatic ß-Cells > C. Catherine Oiry • 174 • CO-005 - Regional heterogeneity of the results of glucagon-like peptide-1 receptor agonists trials on cardiovascular outcomes in type 2 diabetes: a reanalysis of individual participant data > M. Matthieu ROUSTIT • 355 • CO-006 - Cardiovascular impact of discontinuation of renin-angiotensin system inhibitors in advanced chronic kidney disease > B. Bénédicte SAUTENET

Copyright © key4events - All rights reserved